Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medifast Inc (MED)
NYSE:MED
Earnings Data
Report Date
May 05, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.3Last Year’s EPS
0.66Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 18, 2025
|% Change Since: -11.16%
|Next Earnings Date:May 05, 2025
Earnings Call Sentiment|Negative
The call highlighted positive developments like the successful launch of OPTAVIA ASCEND and cost-saving initiatives. However, these were overshadowed by significant challenges, including a steep decline in revenue and active earning coaches, and ongoing customer acquisition difficulties due to the rise of GLP-1 medications. While there are signs of stabilization in coach productivity, the overall sentiment leans towards concern over the company's current trajectory.Company Guidance
During the Medifast Fourth Quarter 2024 Earnings Conference Call, guidance for 2025 focused on several key metrics and priorities. The company emphasized the importance of coach productivity, noting a sequential improvement in revenue per active earning coach, which declined by 5.5% in Q4 2024 compared to a 22.2% decline in Q1 2024. Medifast aims to accelerate customer acquisition and improve coach productivity, leveraging new education resources. They also plan to advance clinical research on the outcomes of customers using OPTAVIA programs alongside GLP-1 medications. The launch of OPTAVIA ASCEND, which featured in 17% of customer orders in January, aims to support customers on GLP-1 medications. Medifast is targeting an additional $15 million to $20 million in cost savings for 2025, following $21 million saved in 2024 through their Fuel for the Future initiatives. Financially, Q4 2024 revenue was $119 million with an EPS of $0.07. The company expects Q1 2025 revenue between $100 million to $120 million and anticipates an EPS range from $0.00 to a loss of $0.50 per share.OPTAVIA ASCEND Launch and Positive Reception
The OPTAVIA ASCEND product line launched in December 2024, targeting GLP-1 medication users and those managing weight loss. It was well received, with 17% of customer orders in January including ASCEND products, indicating strong initial traction.
Cost Reduction Success
The Fuel for the Future initiative delivered $21 million in cost savings in 2024, exceeding initial targets, with an expectation of an additional $15 million to $20 million in savings in 2025.
Improvement in Coach Productivity
There was a third consecutive quarter of moderating declines in revenue per active earning coach, improving from a negative 22.2% in Q1 2024 to a negative 5.5% in Q4 2024.
---
MED Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MED Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 18, 2025 | $16.13 | $14.29 | -11.41% |
| Nov 04, 2024 | $18.81 | $20.40 | +8.45% |
| Aug 05, 2024 | $20.86 | $20.27 | -2.83% |
| Apr 29, 2024 | $35.51 | $27.53 | -22.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Medifast Inc (MED) report earnings?
Medifast Inc (MED) is schdueled to report earning on May 05, 2025, TBA Not Confirmed.
What is Medifast Inc (MED) earnings time?
Medifast Inc (MED) earnings time is at May 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MED EPS forecast?
MED EPS forecast for the fiscal quarter 2025 (Q1) is -0.3.
---